You can buy or sell Abbott and other stocks, options, ETFs, and crypto commission-free!
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. Read More The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Abbott Park, Illinois
52 Week High
52 Week Low
What Makes Abbott (ABT) a New Buy Stock
Abbott (ABT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Abbott (ABT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zac...
Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results
Abbott Lifesciences ABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial.
Abbott's Alinity m CE Mark'd
Abbott (NYSE:ABT) announces that its Alinity m molecular diagnostic system is now CE Mark certified. Initial assays include HIV-1, hepatitis B and C viruses, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium and high-risk HPV. The product is not approved in the U.S....
Expected Apr 17, Pre-Market